Synapse

← Hagop M. Kantarjian

Papers by Hagop M. Kantarjian

Page 7 · newest first

  1. IDH1/IDH2 Inhibition in Acute Myeloid LeukemiaFrontiers in Oncology · 2021
  2. An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemiaAmerican Journal of Hematology · 2021
  3. Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemiaCancer · 2021
  4. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approachCancer · 2021
  5. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysisCancer Medicine · 2021
  6. Nivolumab maintenance in high-risk acute myeloid leukemia patients: a single-arm, open-label, phase II studyBlood Cancer Journal · 2021
  7. Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017American Journal of Hematology · 2021
  8. Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosisBlood Cancer Journal · 2021
  9. Long‐term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome–positive leukemia resistant or intolerant to prior therapyEuropean Journal Of Haematology · 2021
  10. Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabineAmerican Journal of Hematology · 2021
  11. Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1‐mutated acute myeloid leukaemiaBritish Journal of Haematology · 2021
  12. Acute myeloid leukemia: current progress and future directionsBlood Cancer Journal · 2021
  13. Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22Clinical Cancer Research · 2021
  14. Decitabine and venetoclax for IDH1/2 ‐mutated acute myeloid leukemiaAmerican Journal of Hematology · 2021
  15. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemiaLeukemia · 2021
  16. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemiaBlood Cancer Journal · 2021
  17. Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline AlterationsFrontiers in Oncology · 2021
  18. Distinct Immunophenotypes of T Cells in Bronchoalveolar Lavage Fluid From Leukemia Patients With Immune Checkpoint Inhibitors-Related Pulmonary ComplicationsFrontiers in Immunology · 2021
  19. Type I interferon upregulation and deregulation of genes involved in monopoiesis in chronic myelomonocytic leukemiaLeukemia Research · 2021
  20. Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic SyndromesJournal of Clinical Oncology · 2021
  21. Phase 2 study of lenalidomide maintenance for patients with high‐risk acute myeloid leukemia in remissionCancer · 2021
  22. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysisLeukemia · 2021
  23. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AMLBlood Advances · 2020
  24. Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experienceLeukemia & lymphoma/Leukemia and lymphoma · 2020
  25. Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 InhibitorsBlood Cancer Discovery · 2020
  26. Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortalityAmerican Journal of Hematology · 2020
  27. Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of TransplantActa Haematologica · 2020
  28. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemiaCancer · 2020
  29. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemiaBlood Advances · 2020
  30. Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and OpticBlood · 2020
  31. Improved Survival of Patients with Myelofibrosis in the Last DecadeBlood · 2020
  32. Outcomes of TP53-Mutant Acute Myeloid Leukemia with Venetoclax and DecitabineBlood · 2020
  33. Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II TrialBlood · 2020
  34. Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of ResponseBlood · 2020
  35. Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 MutationsBlood · 2020
  36. Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)Blood · 2020
  37. Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and DecitabineBlood · 2020
  38. Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab RegimensBlood · 2020
  39. Cladribine, Idarubicin, Cytarabine (ara-C), and Venetoclax in Treating Patients with Acute Myeloid Leukemia and High-Risk Myelodysplastic SyndromeBlood · 2020
  40. Roleof Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blina): Results from a Phase 2 StudyBlood · 2020
  41. Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 StudyBlood · 2020
  42. The Comparison of Frontline Lower-Dose Dasatinib 50 Mg/Day to Standard-Dose Dasatinib 100 Mg/Day in Newly Diagnosed Chronic Myeloid Leukemia: A Propensity Score AnalysisBlood · 2020
  43. Outcome of Patients with T-Cell Acute Lymphoblastic Leukemia/Lymphoma with Early T-Cell Precursor-like Immunophenotype with Strong CD5 ExpressionBlood · 2020
  44. Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and DasatinibBlood · 2020
  45. Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase InhibitorsBlood · 2020
  46. Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)Blood · 2020
  47. Evolutionary Action Score Identifies a Subset of TP53 Mutated Myelodysplastic Syndrome with Favorable PrognosisBlood · 2020
  48. Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)Blood · 2020
  49. Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with FLT3 MutationsBlood · 2020
  50. Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD ResultsBlood · 2020